文献速递淋巴瘤

维奈克拉联合伊布替尼在边缘区淋巴瘤中诱导持久临床缓解

Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.
PubMed 文献 · Blood Adv · 2026-01-01

单中心2期试验评估每日伊布替尼联合维奈克拉治疗边缘区淋巴瘤,15例可评估安全性,14例纳入疗效分析。总缓解率79%,最佳完全缓解率57%,高于伊布替尼单药历史对照的3%。MRD阴性完全缓解患者可中断治疗并维持持久无病状态。

要点

  • 伊布替尼560mg每日联合维奈克拉递增至400mg每日,16周完全缓解率29%。
  • 最佳完全缓解率57%,显著高于伊布替尼单药历史对照的3%(P<.001)。
  • MRD阴性完全缓解患者可中断治疗,中位4年时4例仍无病。

核心结论

  • 伊布替尼联合维奈克拉治疗边缘区淋巴瘤安全有效,完全缓解率高于伊布替尼单药。
  • MRD阴性完全缓解患者可进入选择性治疗中断,并观察到持久无病状态。

研究设计与样本

  • 单中心2期试验,每日口服伊布替尼560mg,4周后加用维奈克拉并递增至400mg每日,持续至疾病进展或毒性。
  • 15例边缘区淋巴瘤患者接受治疗,14例纳入疗效分析,15例可评估安全性。
  • 主要终点为第16周完全缓解率,通过流式细胞术评估骨髓和外周血MRD。

主要发现

  • 总缓解率79%(95%CI 49-95),完全缓解率43%(95%CI 18-71),基于FDG-PET评估。
  • CT评估第16周完全缓解率29%(95%CI 8-58),56周内最佳完全缓解率57%(95%CI 37-80)。
  • 第56周MRD清除率40%,6例MRD阴性完全缓解患者进入选择性治疗中断,中位4年时4例仍无病。
  • 中位随访5.5年,5年无进展生存率估计为56%(95%CI 27-78)。

关键数值与推荐

  • 最佳完全缓解率57%(95%CI 37-80)对比伊布替尼单药历史对照3%(P<.001)。
  • 第16周CT评估完全缓解率29%(95%CI 8-58),FDG-PET评估完全缓解率43%(95%CI 18-71)。
  • 5年无进展生存率56%(95%CI 27-78),中位随访5.5年。

临床怎么用

  • 伊布替尼联合维奈克拉可作为边缘区淋巴瘤的有效治疗方案,完全缓解率优于伊布替尼单药。
  • MRD阴性完全缓解患者可考虑选择性治疗中断,以实现持久无病状态。

局限性

  • 单中心、小样本2期试验,结果需更大规模研究验证。
  • 历史对照比较可能存在偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oral ibrutinib and venetoclax (I+V) demonstrate activity as monotherapy in marginal zone lymphoma (MZL), with low complete response (CR) rates. I+V has shown good clinical activity with acceptable tolerability in other malignancies. We conducted a single-site, phase 2 trial of daily I+V in patients with MZL. Ibrutinib commenced at 560 mg daily; after 4 weeks, venetoclax commenced with weekly dose escalation to 400 mg daily. Combination therapy continued until disease progression or toxicity. The primary end point was week 16 CR. Minimal residual disease (MRD) was assessed by flow cytometry in bone marrow and peripheral blood. Patients achieving eradication of MRD could enter elective treatment interruption (ETI). Fifteen patients with MZL were treated; 14 are included in efficacy analysis, and 15 were evaluable for safety. Overall response was 79% (95% confidence interval [CI], 49-95) by F-fluorodeoxyglucose-positron-emission tomography (CR rate, 43%; 95% CI, 18-71). By computed tomography, 16-week CR rate was 29% (95% CI, 8-58). Best response within 56 weeks was 57% CR (95% CI, 37-80), which is higher than historic ibrutinib-monotherapy control (3% CR; P< .001). MRD clearance at week 56 was 40%. Six MRD-negative CR patients entered ETI, with 4 remaining disease-free at a median of 4 years. With a median follow-up of 5.5 years for the whole cohort, the 5-year progression-free survival estimate was 56% (95% CI, 27-78). I+V is safe and effective for MZL, with higher CR than with ibrutinib. Durable, ongoing CR was observed in MRD-negative patients. This trial was registered at www.clinicaltrials.gov as #NCT02471391.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Handunnetti SM, Khot A, Blombery P, et al. Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma. Blood Adv. 2026. PMID: 41380113. doi:10.1182/bloodadvances.2025016646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。